Alpha Fetoprotein (AFP)
Solubilization Demonstration

Alpha Fetoprotein (AFP)

Harnessing Nature

Alpha Fetoprotein
AFP Rendering

Alpha Fetoprotein (AFP) is a human protein produced by the embryo during fetal development and serves two critical functions:

  1. Normalizes immune system responses so the mother’s immune cells don’t attack the embryo; and
  2. Picks up nutrients from the mother and delivers them to the embryo.

Symptoms of autoimmune diseases (Myasthenia Gravis, Multiple Sclerosis, Arthritis etc.) go into remission during pregnancy. This correlates very well with the rise and fall of AFP.

AFP enters maternal bloodstream and picks hydrophobic substances, needed by rapidly growing embryo. AFP circulates until it finds receptors which are present on all embryonic cells. It then binds to the receptor and is transported into cell where the payload is released. After birth, the production of AFP stops and the receptors disappear.

Most cancer cells like embryonic cells express AFP receptors while healthy cells do not.

By attaching a chemotherapy payload to AFP we can selectively deliver toxins to cancer cells bypassing normal cells.This results in increased efficacy and a significant reduction in toxicity.

Pipeline

Therapy Indication Partners Discovery Pre-Clinical Phase I Phase II
ACT-101
(AFP)
Autoimmune
Inflammatory Bowel Disease (Crohn's/Colitis)
 
Myasthenia Gravis (muscle weakness)
 
Hashimoto Disease
 
Multiple Sclerosis, Others
 
ACT-901
(AFP + paclitaxel)
Targeted Oncology
Solid and liquid tumors
Collaboration University Health Network
Princess Margaret Cancer Center
 
ACT-902
(AFP + thapsigargin)
Targeted Oncology
Solid and liquid tumors
Collaboration University Health Network
 
ACT-903
(AFP + linker + maytansine)
Targeted Oncology
Solid and liquid tumors
Collaboration Polytherics (Abzena) U.K.